Atypical hemolytic uremic syndrome (aHUS) is a rare type of HUS associated with dysregulation of the alternative complement pathway. We herein report the findings of a 43-year-old woman who developed aHUS two days after myomectomy. The serum C3 level was low and the sheep erythrocyte hemolytic assay showed a moderate hemolysis. The renal insufficiency progressed despite performing plasma exchange therapy, although a partial hematological response was observed. Thus, the patient was subsequently treated with the anti-C5 antibody eculizumab, which promptly improved and normalized the renal function. Although aHUS after surgery has rarely been reported, it needs to be promptly recognized and treated with eculizumab to prevent irreversible renal damage.
Introduction
Thrombotic microangiopathies (TMAs) are severe disorders caused by endothelial cell damage, platelet activation and thrombus formation, which are clinically characterized by thrombocytopenia, intravascular hemolysis accompanied by red cell fragmentation and organ failure (1) (2) (3) (4) . TMAs are separated into two broad categories: thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS). TTP is associated with a severe deficiency of the von Willebrand factor cleaving metalloprotease ADAMTS13 activity, which is frequently caused by the generation of its autoantibody, and typically involves the central nervous system. On the other hand, HUS predominantly involves the renal microvasculature and causes renal failure. The typical or classical type of HUS is caused by Shiga toxin-producing organisms, such as enterotoxigenic Escherichia coli or Shigella dysenteriae, and is accompanied by bloody diarrhea in the majority of cases. On the other hand, secondary HUS or TMA is caused by various diseases or conditions that may cause systemic endothelial cell damage, such as malignant hypertension, septicemia, autoimmune disorders, malignancies and immunosuppressive therapies after hematopoietic cell transplantation (1) (2) (3) (4) .
Atypical HUS (aHUS) is caused by dysregulation of the alternative complement pathway on the surface of endothelial cells, which is due to genetic abnormalities of proteins involved in this pathway or the development of autoantibodies against these components (1) (2) (3) (4) . Tight control of the alternative complement pathway, which is constitutively active, is required to limit unregulated generation of C3 convertase and subsequent activation of C5 leading to the formation of the membrane attack complex at the vascular endothelial cell surface causing endothelial cell damage, platelet activation and thrombosis. Thus, this pathway is tightly regulated by soluble or membrane-bound regulators, such as complement factor H (CFH) and membrane cofactor protein.
Excessive activation of the complement system was first implicated in the aHUS pathogenesis by low plasma C3 levels in a patient with aHUS and his family members. This was followed by the identification of mutations in the CFH gene in aHUS patients in 1998 (4, 5) . Since then, various abnormalities of the complement regulatory factors or C3 itself, 
Case Report
A 43-year-old previously healthy woman was admitted to a hospital for surgery involving a uterine myoma, measuring 9×5×3 cm in size. She had previously undergone tonsillectomy without any complications. She had no family history of thrombocytopenia or renal diseases. Preoperative laboratory data did not show any abnormality in renal function, liver function, coagulation and complete blood count (Table 1). She underwent laparoscopic myomectomy without any significant complications during the operation. However, 10 hours after surgery, hemorrhagic leakage from the abdominal drain site started, and the amount of bleeding rapidly increased to 1,900 mL. Subsequently, she became hypotensive, with her Hb and platelet counts decreasing to 2.8 g/dL and 39×10 9 /L, respectively, and her creatinine level increased to 2.21 mg/dL. Because the hypotension was considered to be caused by ongoing intra-abdominal hemorrhage, she was transfused with red blood cells and underwent emergency laparotomy for hemostasis. Although her Hb increased to 10.0 g/dL with a temporary cessation of hemorrhage, the hemorrhagic leakage started again.
On postoperative day two, she was transferred to the intensive care unit of our hospital for further examination and treatment. On physical examination, her body temperature was 36.9 , neurological abnormalities were absent and there was subcutaneous bleeding around the drain site. An examination of her blood revealed anemia, thrombocytopenia, elevation of serum lactate dehydrogenase (LDH) and progressing renal insufficiency (Table 1) . Coagulation studies were normal except for a slight increase in the serum fibrinogen/fibrin degradation product (FDP) level. Disseminated intravascular coagulation (DIC) was suspected because of persistent hemorrhage with thrombocytopenia and an increase in the FDP level. Therefore, gabexate mesilate was administered at a dose of 1,000 mg with platelet transfusion. Urinalysis showed 2 + protein, more than 100 RBC and 5 to 9 WBC per high-power field (×400) as well as a few hyaline, epithelial cell and granular casts per low-power field (× 100). The patient developed pulmonary edema caused by acute renal failure, and her respiratory condition deteriorated. Continuous hemodiafiltration (CHDF) and noninvasive positive ventilation were started. Although hemorrhage from the drain decreased, severe anemia and thrombocytopenia did not improve despite frequent blood transfusions. On postoperative day five, serum LDH increased to 3,629 IU/L. Haptoglobin was below the detectable level and fragmented red blood cells were observed at 8.9% in the peripheral blood. Results of the direct and indirect Coombs tests as well as those for various autoimmune antibodies, including anti-nuclear antibody, anti-double-stranded DNA antibody, anti-neutrophil cytoplasmic antibody and anticardiolipin antibody, were negative. The possibility of DIC was not plausible, because there was no decrease in the fibrinogen level or further increase in the FDP level despite the steady decrease in platelet count. Based on these clinical and laboratory data, the patient was diagnosed with TMA. Platelets were transfused on postoperative days three, five and six. Although the first transfusion coincided with the rising LDH level, the later transfusions were accompanied by a decreasing LDH level associated with PE. Furthermore, platelet transfusions did not have any significant effect on the creatinine level. Thus, we considered that the platelet transfusion did not affect TMA in the present case. We performed PE on postoperative days five, six and seven with 36 units of fresh frozen plasma (Figure) . Laboratory data improved after performing PE three times, with the platelet count increasing to 57×10 9 /L, hemoglobin to 7.1 g/ dL and LDH to 445 IU/L on postoperative day eight. However, renal dysfunction did not improve with creatinine remaining at high levels (4-5 mg/dL). On postoperative day eight, hemodialysis (HD) was started three days a week instead of CHDF. The serum ADAMTS13 activity on postoperative day five was 72.6% and its inhibitor was not detected. Furthermore, the serum C3 and C4 levels on postoperative day six were slightly decreased, while CH50 was within the normal range (Table 2) . Thus, we considered this case to involve aHUS rather than TTP. Therefore, PE was discontinued, and the eculizumab therapy (900 mg every week for four weeks) was initiated on postoperative day nine. With a rapid decrease in the CH50 level, which should reflect the inhibitory effect of eculizumab on C5, the serum C3 and C4 levels increased to their normal values soon after eculizumab therapy was started ( Table 2 ). The patient's platelet count and Hb level approached the normal range on day 23. Furthermore, after starting eculizumab, the patient started to recover from anuria, and urinary output started to increase considerably after the second infusion with a reciprocal rapid decrease in the creatinine level (Figure) . Thus, HD was successfully stopped on postoperative day 20, and the patient was discharged on postoperative day 31. After discharge, a maintenance therapy with eculizumab (1,200 mg biweekly) was started from postoperative day 43. The dose of eculizumab was gradually tapered off from 5 months after discharge and was stopped 6 months later. Six weeks later, on her last visit to the outpatient office, the CH50 level had returned to normal for the first time since starting the eculizumab therapy. Although no manifestations of recurrence have so far been observed on close monitoring of various laboratory data, including the levels of C3, LDH, haptoglobin, bilirubin and creatinine as well as reticulocyte counts, we are prepared to start the eculizumab therapy again on any sign of recurrence.
Despite the fact that the sample obtained two days after completion of PE was used, the hemolytic assay using sheep red blood cells performed at the Department of Blood Transfusion Medicine, Nara Medical University (7-9), showed that the patient's plasma induced a moderate degree of hemolysis (39%) in comparison to the value obtained under the conditions where CFH in the normal plasma was completely inhibited by a specific monoclonal antibody. Additionally, we did not detect an anti-CFH autoantibody or abnormalities of the CFH-related (CFHR) proteins, CFHR1 and CFRH3, based on Western blot and genetic analyses.
Discussion
We herein report a case of adult-onset aHUS developing after surgery that was successfully treated with eculizumab. The patient was diagnosed with TMA because of typical laboratory findings of hemolytic anemia with red cell fragmentation, thrombocytopenia and renal failure. The patient showed neither fever nor any neurological abnormalities, which are typically observed in TTP. The possibility of TTP was subsequently ruled out, because the serum ADAMTS13 activity was not significantly reduced and its inhibitor was not detected. The typical type of HUS and secondary HUS were ruled out, because there were no symptoms of infection by Shiga toxin-producing organisms nor were there diseases or conditions known to cause HUS through diffuse endothelial cell damage. On the other hand, dysregulation of the complement system was suggested by the decreased serum C3 level and the increased hemolytic activity revealed by the sheep erythrocyte hemolysis assay. Finally, the renal and hematological abnormalities showed a rapid and complete response to the eculizumab therapy after only partially responding to PE, which strongly supports the diagnosis of aHUS. Typically, aHUS affects young patients and different members of the same family with a recurrent and relapsing clinical course and results in end-stage renal disease or death in more than half of patients (1-4). However, sporadic cases are in fact more frequent than familial cases, and about 40% of patients first develop aHUS in adulthood triggered by events enhancing the complement activation, such as infection or pregnancy (4). The diagnosis of aHUS could be confirmed by detection of genetic abnormalities of the complement system or autoantibodies against CFH. However, this confirmation could take several weeks. Furthermore, these abnormalities could not be detected in up to half of patients with aHUS even after thorough investigations. Although a few diagnostic tests, such as measuring the concentration of complement proteins in the serum and the sheep erythrocyte lysis assay, are available, these assays lack sensitivity and specificity (5). For example, it was reported that the serum C3 level was low at the first assessment in 77 of 214 patients (35.9%) later diagnosed with aHUS (10) , while recent studies have demonstrated complement activation to be present in patients with ADAMTS13-deficient TTP (11) . On the other hand, although eculizumab shows a remarkable therapeutic effect on aHUS, the extent of renal function recovery correlates inversely with the time interval between the onset of an episode of aHUS and the initiation of eculizumab treatment (6) . Thus, in the absence of underlying diseases or conditions associated with the typical HUS or the secondary TMAs, it is recommended to start the eculizumab therapy for TMA patients with non-deficient ADAMTS13 activity (not less than 5-10%) if they are not responding completely to PE or if renal injury is progressing despite a hematological response (1, 2, 6) . The mechanisms underlying progressive renal failure despite hematological response to PE remain unknown. However, the threshold for complement activation causing renal impairment is supposed to be lower than that causing explicit hematological disturbances, because aHUS typically presents with severe renal insufficiency associated with only moderate thrombocytopenia (1-3). Thus, it is speculated that PE ameliorates the complement activation enough for a hematological response but not enough to prevent ongoing renal damage. Irrespective of the mechanisms involved, the present case illustrates the importance of making an early diagnosis of aHUS and supports the utility of the recommended therapeutic strategy.
The issues of optimal treatment duration of eculizumab and ways to taper off eculizumab have remained largely unexplored, especially for patients without identified genetic causes of aHUS (6) . Eculizumab was gradually tapered off and very recently stopped in the present case, and we are continuing to monitor for signs of a relapse. In this regard, the development of laboratory methods that can accurately indicate endothelial damage early and can predict aHUS relapse are urgently needed (5, 12) . As for a biomarker for endothelial damage, a very recent report revealed that plasma thrombomodulin levels are elevated in most cases of aHUS and decrease to near normal levels after eculizumab therapy (13) . However, further studies are needed to evaluate the possible clinical value of thrombomodulin as well as other biomarkers for complement activation, inflammation, thrombosis and renal injury relevant to aHUS (13) for predicting recurrence of aHUS after stopping eculizumab treatment.
In the present case, the onset of aHUS occurred after gynecological surgery. It has been reported that a clinical syndrome resembling TTP, so-called "postoperative TTP" (pTTP), may rarely occur after surgical procedures (14) . The clinical features of pTTP are different from those of the present case, because pTTP usually begins five to nine days after cardiac or vascular surgeries and is very frequently accompanied by fever (72.7%) and neurological manifestations (87.8%) (14, 15) . The etiology of pTTP remains unknown because a severely reduced ADAMTS13 activity or an increased ADAMTS13 antibody level has not been reported in cases with pTTP despite showing similar clinical features with TTP (14) . However, because these patients frequently show moderate thrombocytopenia and severe renal failure with a fatality rate similar to those with aHUS (nearly 30%), it is tempting to speculate that some of the pTTP cases might actually represent episodes of aHUS triggered by surgical procedures and stress.
A recurrence of aHUS is not unusual after renal transplantation in aHUS patients with advanced renal insufficiency (16) . It is also well established that organ transplantation and calcineurin inhibitor therapy are major causes for secondary TMA (1-3) . However, only three cases of aHUS developing after non-transplantation surgeries have been reported (Table 3) (17) (18) (19) . In contrast to the typical cases of pTTP, these patients developed signs of TMA within a few days after surgery. In two of the cases, genetic abnormalities in the complement regulation system were identified (Cases 2 and 3) (18, 19) . Interestingly, one of these patients first developed aHUS after nephrectomy at the age of 70, whereas his son developed aHUS at the age of two and experienced seven recurrences of aHUS (Case 2) (19) . Genetic mutations in the complement regulatory system were not examined in the remaining case (Case 1) (17) . However, the patient had a decreased plasma C3 level and showed a good hematological response to PE without showing any renal response, thus requiring continued HD, as is often the case with aHUS. Therefore, postoperative aHUS should be suspected in patients who develop TMA soon after surgery and show progressive renal dysfunction despite hematological response to PE. Initiation of the eculizumab therapy without delay in these cases should prevent the occurrence of irreversible end-stage renal failure.
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